BioCentury
ARTICLE | Product Development

Fewer is better: master protocols need to replace the deluge of small, inadequate studies for COVID-19

Guest Commentary: Master protocols are urgently needed to expedite COVID-19 therapies

March 27, 2020 1:00 AM UTC
Updated on Mar 28, 2020 at 12:18 AM UTC

Nobody wants to waste already strained clinical resources and precious time with a scattershot approach to testing treatments for COVID-19. The deluge of small, poor-quality studies that has been unleashed is standing in the way of finding effective treatments, and risking harm to patients with unsafe agents and unknown drug-drug interactions.

Multiple small and inadequately controlled studies have contributed to controversial claims of drug effectiveness. As a result, trials of remdesivir, widely regarded a promising antiviral, have had a difficult time enrolling patients in the outbreak’s original epicenter of China. ...

BCIQ Company Profiles

Brii Biosciences Ltd.